journal
MENU ▼
Read by QxMD icon Read
search

Lancet Infectious Diseases

journal
https://www.readbyqxmd.com/read/30420230/familiar-barriers-still-unresolved-a-perspective-on-the-zika-virus-outbreak-research-response
#1
REVIEW
Marion Koopmans, Xavier de Lamballerie, Thomas Jaenisch
Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children...
November 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30420229/the-global-antibiotic-research-and-development-partnership-gardp-a-not-for-profit-antibiotic-development-organisation
#2
Laura Jv Piddock
No abstract text is available yet for this article.
November 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30409683/attributable-deaths-and-disability-adjusted-life-years-caused-by-infections-with-antibiotic-resistant-bacteria-in-the-eu-and-the-european-economic-area-in-2015-a-population-level-modelling-analysis
#3
Alessandro Cassini, Liselotte Diaz Högberg, Diamantis Plachouras, Annalisa Quattrocchi, Ana Hoxha, Gunnar Skov Simonsen, Mélanie Colomb-Cotinat, Mirjam E Kretzschmar, Brecht Devleesschauwer, Michele Cecchini, Driss Ait Ouakrim, Tiago Cravo Oliveira, Marc J Struelens, Carl Suetens, Dominique L Monnet
BACKGROUND: Infections due to antibiotic-resistant bacteria are threatening modern health care. However, estimating their incidence, complications, and attributable mortality is challenging. We aimed to estimate the burden of infections caused by antibiotic-resistant bacteria of public health concern in countries of the EU and European Economic Area (EEA) in 2015, measured in number of cases, attributable deaths, and disability-adjusted life-years (DALYs). METHODS: We estimated the incidence of infections with 16 antibiotic resistance-bacterium combinations from European Antimicrobial Resistance Surveillance Network (EARS-Net) 2015 data that was country-corrected for population coverage...
November 5, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30409682/public-health-burden-of-antimicrobial-resistance-in-europe
#4
Evelina Tacconelli, Maria Diletta Pezzani
No abstract text is available yet for this article.
November 5, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30389483/blood-pcr-testing-for-enteroviruses-in-young-children
#5
Kevin Messacar, Samuel R Dominguez
No abstract text is available yet for this article.
October 30, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30389482/assessment-of-blood-enterovirus-pcr-testing-in-paediatric-populations-with-fever-without-source-sepsis-like-disease-or-suspected-meningitis-a-prospective-multicentre-observational-cohort-study
#6
Jérémy Lafolie, André Labbé, Anne Sophie L'Honneur, Fouad Madhi, Bruno Pereira, Marion Decobert, Marie Noelle Adam, François Gouraud, Frédéric Faibis, Francois Arditty, Stéphanie Marque-Juillet, Marie Aline Guitteny, Gisele Lagathu, Matthieu Verdan, Flore Rozenberg, Audrey Mirand, Hélène Peigue-Lafeuille, Cécile Henquell, Jean-Luc Bailly, Christine Archimbaud
BACKGROUND: Enteroviruses are the most frequent cause of acute meningitis and are seen increasingly in sepsis-like disease and fever without source in the paediatric population. Detection of enterovirus in cerebrospinal fluid (CSF) specimens by PCR is the gold standard diagnostic test. Our aim was to assess a method of detecting enterovirus in blood specimens by PCR. METHODS: We did a prospective, multicentre, observational study at 35 French paediatric and emergency departments in 16 hospitals...
October 30, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30389481/corrections
#7
(no author information available yet)
No abstract text is available yet for this article.
October 30, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30385159/incarceration-drug-use-and-infectious-diseases-a-syndemic-still-not-addressed
#8
Nickolas Zaller, Lauren Brinkley-Rubinstein
No abstract text is available yet for this article.
October 29, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30385158/violence-and-community-mistrust-hamper-ebola-response
#9
Sophie Cousins
No abstract text is available yet for this article.
October 29, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30385157/incarceration-history-and-risk-of-hiv-and-hepatitis-c-virus-acquisition-among-people-who-inject-drugs-a-systematic-review-and-meta-analysis
#10
Jack Stone, Hannah Fraser, Aaron G Lim, Josephine G Walker, Zoe Ward, Louis MacGregor, Adam Trickey, Sam Abbott, Steffanie A Strathdee, Daniela Abramovitz, Lisa Maher, Jenny Iversen, Julie Bruneau, Geng Zang, Richard S Garfein, Yung-Fen Yen, Tasnim Azim, Shruti H Mehta, Michael-John Milloy, Margaret E Hellard, Rachel Sacks-Davis, Paul M Dietze, Campbell Aitken, Malvina Aladashvili, Tengiz Tsertsvadze, Viktor Mravčík, Michel Alary, Elise Roy, Pavlo Smyrnov, Yana Sazonova, April M Young, Jennifer R Havens, Vivian D Hope, Monica Desai, Ellen Heinsbroek, Sharon J Hutchinson, Norah E Palmateer, Andrew McAuley, Lucy Platt, Natasha K Martin, Frederick L Altice, Matthew Hickman, Peter Vickerman
BACKGROUND: People who inject drugs (PWID) experience a high prevalence of incarceration and might be at high risk of HIV and hepatitis C virus (HCV) infection during or after incarceration. We aimed to assess whether incarceration history elevates HIV or HCV acquisition risk among PWID. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, and PsycINFO databases for studies in any language published from Jan 1, 2000 until June 13, 2017 assessing HIV or HCV incidence among PWID...
October 29, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30344084/leave-no-one-behind-response-to-new-evidence-and-guidelines-for-the-management-of-cryptococcal-meningitis-in-low-income-and-middle-income-countries
#11
REVIEW
Angela Loyse, Jessica Burry, Jennifer Cohn, Nathan Ford, Tom Chiller, Isabela Ribeiro, Sinata Koulla-Shiro, Janneth Mghamba, Angela Ramadhani, Rose Nyirenda, Sani H Aliyu, Douglas Wilson, Thuy Le, Rita Oladele, Sokoine Lesikari, Conrad Muzoora, Newton Kalata, Elvis Temfack, Yacouba Mapoure, Victor Sini, Duncan Chanda, Meshack Shimwela, Shabir Lakhi, Jonathon Ngoma, Lilian Gondwe-Chunda, Chase Perfect, Amir Shroufi, Isabelle Andrieux-Meyer, Adrienne Chan, Charlotte Schutz, Mina Hosseinipour, Charles Van der Horst, Jeffrey D Klausner, David R Boulware, Robert Heyderman, David Lalloo, Jeremy Day, Joseph N Jarvis, Marcio Rodrigues, Shabbar Jaffar, David Denning, Chantal Migone, Megan Doherty, Olivier Lortholary, Françoise Dromer, Muirgen Stack, Síle F Molloy, Tihana Bicanic, Joep van Oosterhout, Peter Mwaba, Cecilia Kanyama, Charles Kouanfack, Sayoki Mfinanga, Nelesh Govender, Thomas S Harrison
In 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care. WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine...
October 18, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30342828/outbreak-of-multidrug-resistant-tuberculosis-in-south-africa-undetected-by-who-endorsed-commercial-tests-an-observational-study
#12
Ndivhuho A Makhado, Edith Matabane, Mauro Faccin, Claire Pinçon, Agathe Jouet, Fairouz Boutachkourt, Léonie Goeminne, Cyril Gaudin, Gugu Maphalala, Patrick Beckert, Stefan Niemann, Jean-Charles Delvenne, Michel Delmée, Lufuno Razwiedani, Maphoshane Nchabeleng, Philip Supply, Bouke C de Jong, Emmanuel André
BACKGROUND: Global roll-out of rapid molecular assays is revolutionising the diagnosis of rifampicin resistance, predictive of multidrug-resistance, in tuberculosis. However, 30% of the multidrug-resistant (MDR) strains in an eSwatini study harboured the Ile491Phe mutation in the rpoB gene, which is associated with poor rifampicin-based treatment outcomes but is missed by commercial molecular assays or scored as susceptible by phenotypic drug-susceptibility testing deployed in South Africa...
October 17, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30342827/occult-rifampicin-resistant-tuberculosis-better-assays-are-needed
#13
Ebrahim Variava, Neil Martinson
No abstract text is available yet for this article.
October 17, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30340981/confronting-the-threat-of-bioterrorism-realities-challenges-and-defensive-strategies
#14
REVIEW
Manfred S Green, James LeDuc, Daniel Cohen, David R Franz
Global terrorism is a rapidly growing threat to world security, and increases the risk of bioterrorism. In this Review, we discuss the potential threat of bioterrorism, agents that could be exploited, and recent developments in technologies and policy for detecting and controlling epidemics that have been initiated intentionally. The local and international response to infectious disease epidemics, such as the severe acute respiratory syndrome and west African Ebola virus epidemic, revealed serious shortcomings which bioterrorists might exploit when intentionally initiating an epidemic...
October 16, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30337261/metagenomics-for-investigation-of-an-unusual-meningococcal-outbreak
#15
Dominique A Caugant
No abstract text is available yet for this article.
October 15, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30337260/analysis-of-the-clinical-antibacterial-and-antituberculosis-pipeline
#16
REVIEW
Ursula Theuretzbacher, Simon Gottwalt, Peter Beyer, Mark Butler, Lloyd Czaplewski, Christian Lienhardt, Lorenzo Moja, Mical Paul, Sarah Paulin, John H Rex, Lynn L Silver, Melvin Spigelman, Guy E Thwaites, Jean-Pierre Paccaud, Stephan Harbarth
This analysis of the global clinical antibacterial pipeline was done in support of the Global Action Plan on Antimicrobial Resistance. The study analysed to what extent antibacterial and antimycobacterial drugs for systemic human use as well as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pathogens included in the WHO priority pathogen list and their innovativeness measured by their absence of cross-resistance (new class, target, mode of action). As of July 1, 2018, 30 new chemical entity (NCE) antibacterial drugs, ten biologics, ten NCEs against Mycobacterium tuberculosis, and four NCEs against C difficile were identified...
October 15, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30337259/outbreak-of-neisseria-meningitidis-serogroup-c-outside-the-meningitis-belt-liberia-2017-an-epidemiological-and-laboratory-investigation
#17
Catherine H Bozio, Jeni Vuong, E Kainne Dokubo, Mosoka P Fallah, Lucy A McNamara, Caelin C Potts, John Doedeh, Miatta Gbanya, Adam C Retchless, Jaymin C Patel, Thomas A Clark, Henry Kohar, Thomas Nagbe, Peter Clement, Victoria Katawera, Nuha Mahmoud, Harouna M Djingarey, Anne Perrocheau, Dhamari Naidoo, Mardia Stone, Roseline N George, Desmond Williams, Alex Gasasira, Tolbert Nyenswah, Xin Wang, LeAnne M Fox
BACKGROUND: On April 25, 2017, a cluster of unexplained illnesses and deaths associated with a funeral was reported in Sinoe County, Liberia. Molecular testing identified Neisseria meningitidis serogroup C (NmC) in specimens from patients. We describe the epidemiological investigation of this cluster and metagenomic characterisation of the outbreak strain. METHODS: We collected epidemiological data from the field investigation and medical records review. Confirmed, probable, and suspected cases were defined on the basis of molecular testing and signs or symptoms of meningococcal disease...
October 15, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30322791/strategies-to-improve-detection-and-management-of-human-parechovirus-infection-in-young-infants
#18
REVIEW
Seilesh Kadambari, Heli Harvala, Peter Simmonds, Andrew J Pollard, Manish Sadarangani
Human parechovirus infections are the second most common cause of viral meningitis in children. These infections are most frequently seen in infants younger than 90 days. Clinical manifestations include encephalitis, meningitis, myocarditis, and sepsis, which can lead to serious neurodevelopmental sequelae in young infants. Molecular techniques, including PCR assays, are the preferred diagnostic methods and have contributed to an increase in reported cases, along with an increasing awareness of the causal role of human parechovirus in infant diseases...
October 12, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30322790/tuberculosis-susceptibility-and-protection-in-children
#19
REVIEW
Robindra Basu Roy, Elizabeth Whittaker, James A Seddon, Beate Kampmann
Children represent both a clinically important population susceptible to tuberculosis and a key group in whom to study intrinsic and vaccine-induced mechanisms of protection. After exposure to Mycobacterium tuberculosis, children aged under 5 years are at high risk of progressing first to tuberculosis infection, then to tuberculosis disease and possibly disseminated forms of tuberculosis, with accompanying high risks of morbidity and mortality. Children aged 5-10 years are somewhat protected, until risk increases again in adolescence...
October 12, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30297322/single-dose-versus-7-day-dose-metronidazole-for-the-treatment-of-trichomoniasis-in-women-an-open-label-randomised-controlled-trial
#20
Patricia Kissinger, Christina A Muzny, Leandro A Mena, Rebecca A Lillis, Jane R Schwebke, Laura Beauchamps, Stephanie N Taylor, Norine Schmidt, Leann Myers, Peter Augostini, William E Secor, Martina Bradic, Jane M Carlton, David H Martin
BACKGROUND: Among women, trichomoniasis is the most common non-viral sexually transmitted infection worldwide, and is associated with serious reproductive morbidity, poor birth outcomes, and amplified HIV transmission. Single-dose metronidazole is the first-line treatment for trichomoniasis. However, bacterial vaginosis can alter treatment efficacy in HIV-infected women, and single-dose metronidazole treatment might not always clear infection. We compared single-dose metronidazole with a 7-day dose for the treatment of trichomoniasis among HIV-uninfected, non-pregnant women and tested whether efficacy was modified by bacterial vaginosis...
October 5, 2018: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"